Jun 09, 2022 / 07:00PM GMT
Matthew Stanton -
Alright. Welcome, everyone, to the Jefferies Global Healthcare Conference. I'm Matt Stanton. I'm on the Life Science Tools and diagnostics team here at Jefferies. It's my pleasure to have Codexis back with us at the conference again this year. Joining us from the company, we have President and CEO, John Nicols, John, thanks for being here.
John J. Nicols - Codexis, Inc. - President, CEO & Director
Yes, please. Thank you.
Questions and Answers:
Matthew Stanton -I guess to kind of kick off with a big picture question. You have the core enzyme business and the biotherapeutics pipeline. You recently started to break out segment financial performance before unallocated corporate overhead, which I think has been well received based on investor feedback. Can you just talk about how you're thinking about balancing investment in the 2 -- on one hand, you have the Performance Enzyme business, 30%-plus EBIT margins before the corporate overhead and the biotherapeutics pipeline that's consuming cash, especially in
Trustpilot
